Patient Stratification for Precision Medicine In Neuroscience: How Can We Ensure The Right Patients Are Enrolled On The Right Drugs To Treat Their Specific Disease Pathology?
Time: 11:20 am
day: Pre-Conference Day AM Track C
Details:
In a setting where our understanding of disease heterogeneity and subtyping in neuroscience is getting more clearly defined, the role of stratification biomarkers becomes more clearly crucial to clinical trial outcomes.
Key Takeaways:
- Developing biomarkers has to go hand in hand with drug development to develop more sensitive tools to monitor function, cognition etc in a human.
- Using earlier screening process to stratify patients with neuroinflammatory phenotype earlier in disease to ensure greater success in trials
- Harnessing a matrix of endpoints to identify neuroinflammation including cytotoxins, GFAP, soluble TREM2 as more specific markers, NFL, synaptic markers (neurogranulin, Snap 25 and amyloid tau), as well as functional outcomes, cognition and daily living
- Evaluating biomarker utility across different diseases and types of neuroinflammation
*Lunch will be served during this session at 12:30
